About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 48 record(s)
Req # A-2021-000347
Adverse Drug Reaction (ADR) for ZOLPIDEM TARTRATE. Report number: E2B_03415858.Organization: Health Canada
August 2021
Req # A-2021-000348
Adverse Drug Reaction (ADR) for CROMOGLICATE SODIUM. Report number: E2B_03387488.Organization: Health Canada
August 2021
Req # A-2021-000352
Adverse Reaction Reports (AERs) for DESOXIMETASONE. Report numbers: E2B_03706173, E2B_03706156.Organization: Health Canada
August 2021
Req # A-2021-000500
Adverse Drug Reaction (ADR) for ALEMTUZUMAB. Report number: E2B_03387869.Organization: Health Canada
August 2021
Req # A-2021-000502
Adverse Drug Reaction (ADR) for ALEMTUZUMAB. Report number: E2B_03387914.Organization: Health Canada
August 2021
Req # A-2021-000672
Adverse Drug Reaction (ADR) for PREDNISOLONE SODIUM PHOSPHATE. Report number: E2B_03278670.Organization: Health Canada
August 2021
Req # A-2021-000701
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116197-660, Interim Order for Medical Devices - Performance.Organization: Health Canada
August 2021
Req # A-2021-000705
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109078-620, Management of COVID-19 Medical Devices applications.Organization: Health Canada
August 2021
Req # A-2021-000706
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-108121-589, MDAP (Medical Devices Action Plan) Progress Report.Organization: Health Canada
August 2021
Req # A-2020-000015
Information as to whether or not the Abbreviated New Drug Submission (ANDS) for liraglutide accepted into review in August 2017 is on “intellectual property hold” as described in section 6.2 of Health Canada’s Guidance Document on PatentedMedicines (Notice of Compliance) Regulations.Organization: Health Canada
August 2020